TAP1 and Alzheimer disease: Low expression of SLC6A12, was significantly correlated with ADORA2A, CD40, CSF1, HSPA12B, IRF5, KLF2, NOS3, TAP1, TGFB1, and VSIR. High ADORA2A expression may be a serum biomarker of and may take effect in AD development (Meng et al., 2020).